CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 Concentration for Research — Dosing Standards

Real Peptides Research TeamEditorial

Updated June 17, 20268 min read

58 WORDS

Short answer

Key takeaways

The research-standard concentration for CJC-1295 is 1mg/mL, achieved by reconstituting a 2mg vial with 2mL bacteriostatic water.
Concentrations below 1mg/mL increase injection volume to impractical levels (≥400μL for typical doses), while concentrations above 2mg/mL introduce aggregation risk and visible turbidity.
Peptide degradation in solution is concentration-dependent. At 1mg/mL stored at 2–8°C, CJC-1295 retains 95–97% potency over 28 days.
Reconstitution must use bacteriostatic water (not sterile water or saline), injected slowly down the vial wall to prevent mechanical denaturation of the peptide structure.
Volumetric dosing errors compound at non-standard concentrations. A 10μL measurement error at 0.5mg/mL delivers 5μg variance, while the same error at 2mg/mL delivers 20μg variance.
Temperature excursions above 8°C during storage cause irreversible peptide denaturation. Refrigeration is non-negotiable for maintaining concentration accuracy.

The concentration debate in peptide research isn't about personal preference. It's about whether your data means anything. A research team using 0.5mg/mL CJC-1295 and another using 2mg/mL aren't running the same study, even if the absolute dose matches. The peptide's stability window, degradation rate, and injection volume all shift with concentration, introducing confounding variables that nullify cross-study comparison. Published research protocols consistently specify 1mg/mL as the baseline concentration. Not because it's convenient, but because it's the inflection point where stability, accuracy, and reproducibility align.

Our team has reviewed hundreds of peptide protocols across academic and commercial research settings. The pattern is consistent: the facilities producing the most replicable data use standardised concentration protocols. Not creative variations.

How concentrated should CJC-1295 be for research purposes?

The standard research concentration for CJC-1295 is 1mg/mL, achieved by reconstituting a 2mg lyophilised vial with 2mL bacteriostatic water. This concentration allows precise dosing in microliter volumes (50–200μL per injection), maintains peptide stability for 28 days under refrigeration, and matches the concentration cited in published growth hormone secretagogue studies. Lower concentrations increase injection volume and dilution error; higher concentrations create peptide aggregation risk.

Here's what most protocol guides skip: the concentration you choose doesn't just affect dosing convenience. It determines whether your peptide degrades linearly or exponentially over the storage period. CJC-1295 has a chemical half-life in solution that's concentration-dependent. At 1mg/mL stored at 2–8°C, degradation is approximately 3–5% over 28 days. At 0.25mg/mL, that same degradation curve steepens because the peptide-to-solvent ratio destabilises the amino acid structure. This article covers the mechanism behind concentration-dependent stability, the volumetric calculation errors that occur outside the 1mg/mL standard, and the specific preparation mistakes that compromise potency before the first dose.

Why 1mg/mL Is the Research Standard for CJC-1295

The 1mg/mL concentration emerged as the research standard because it balances three competing constraints: peptide stability, injection volume practicality, and dosing precision. CJC-1295 (with or without DAC modification) is a 30-amino-acid synthetic peptide that binds to growth hormone-releasing hormone (GHRH) receptors. Its potency depends entirely on the structural integrity of that amino acid chain. When lyophilised peptides are reconstituted, the concentration determines how tightly those molecules pack in solution, which directly affects aggregation risk and degradation rate.

At 1mg/mL, a typical research dose of 100–200μg translates to 100–200μL injection volume. Deliverable with standard 0.5mL or 1mL insulin syringes without wasting peptide or introducing volumetric error. Compare that to 0.25mg/mL, where the same 200μg dose requires 800μL. Exceeding the practical injection volume for subcutaneous administration and requiring multiple injection sites or a larger gauge needle. Research teams using multi-site protocols avoid this by standardising at 1mg/mL.

Peptide aggregation. The process where individual molecules clump together and lose bioactivity. Accelerates at concentrations above 2mg/mL. While CJC-1295 is relatively stable compared to highly aggregation-prone peptides like insulin or amyloid-beta fragments, concentrations exceeding 2.5mg/mL introduce visible turbidity in some batches after 7–10 days of refrigerated storage. The 1mg/mL standard sits well below this threshold, ensuring optical clarity and consistent potency across the full 28-day use window.

Reconstitution Protocol: How to Achieve 1mg/mL Concentration

Reconstitution errors are the single largest source of dosing inaccuracy in peptide research. And the mistakes happen before the peptide even touches the syringe. CJC-1295 is supplied as a lyophilised powder in sealed vials, typically in 2mg or 5mg quantities. The reconstitution process determines the final concentration, and precision at this step dictates whether every subsequent dose matches the intended amount.

For a 2mg vial, add exactly 2mL of bacteriostatic water to achieve 1mg/mL. For a 5mg vial, add 5mL. The calculation is linear: divide the total peptide mass (in mg) by the desired concentration (1mg/mL) to get the volume of diluent required. Use bacteriostatic water containing 0.9% benzyl alcohol. Not sterile water, not saline. Bacteriostatic water prevents bacterial growth during the 28-day refrigerated storage period; sterile water does not and should be discarded within 24 hours of mixing.

The injection technique matters: inject the bacteriostatic water slowly down the inside wall of the vial. Never directly onto the lyophilised powder. Direct impact can denature the peptide structure. Let the liquid run down the glass and reconstitute the powder passively. If powder remains after 60 seconds, gently swirl the vial in a circular motion. Do not shake. Agitation introduces air bubbles and mechanical shear stress, both of which reduce potency.

Once reconstituted, CJC-1295 at 1mg/mL must be stored at 2–8°C (standard refrigerator temperature) and used within 28 days. Any temperature excursion above 8°C. Even for 2–3 hours. Causes irreversible protein denaturation. If you're preparing peptides for multi-week protocols, consider whether splitting a 5mg vial into smaller aliquots (e.g., five 1mg vials reconstituted separately) reduces freeze-thaw risk and extends usable lifespan.

CJC-1295 Concentration Comparison

Concentration	Injection Volume for 200μg Dose	Stability at 2–8°C (28 days)	Aggregation Risk	Practical Use Case
0.25mg/mL	800μL (requires multi-site injection)	Moderate. Higher dilution accelerates degradation	Low	Not recommended. Impractical volume
0.5mg/mL	400μL (high volume, larger syringe required)	Moderate. Degradation ~6–8% over 28 days	Low	Acceptable for low-dose protocols only
1mg/mL	200μL (standard insulin syringe compatible)	High. Degradation ~3–5% over 28 days	Low	Research standard. Optimal balance
2mg/mL	100μL (low volume, high precision required)	High. Degradation ~3–5% over 28 days	Moderate. Aggregation possible in some batches	Acceptable for experienced researchers
3mg/mL+	67μL or less (micro-dosing required)	Moderate. Aggregation risk increases sharply	High. Visible turbidity after 7–10 days	Not recommended. Stability compromised

What If: CJC-1295 Concentration Scenarios

What If I Accidentally Reconstituted a 2mg Vial with 4mL Instead of 2mL?

You now have 0.5mg/mL instead of 1mg/mL. The peptide is still usable, but every dose requires double the injection volume. If your protocol calls for 200μg, you'll need to inject 400μL instead of 200μL. The peptide won't degrade faster at this lower concentration, but the larger volume increases injection discomfort and requires a larger syringe. You can't 'fix' this by evaporating water. That would concentrate contaminants and destabilise the peptide. Use the batch as-is and adjust your dosing calculations, or discard it and reconstitute a new vial correctly.

What If the Reconstituted Solution Looks Cloudy After 10 Days?

Visible cloudiness or turbidity indicates peptide aggregation. The amino acid chains are clumping together and losing bioactivity. This typically happens when the concentration exceeds 2mg/mL or when the vial experienced a temperature excursion above 8°C. Cloudy peptide should be discarded. There's no reliable way to reverse aggregation at home. If you're consistently seeing cloudiness at 1mg/mL within 10–14 days, check your refrigerator's actual temperature with a separate thermometer (not the built-in display). Many household refrigerators cycle between 4–10°C, and that upper range accelerates aggregation.

What If I Need to Dose 50μg but My Concentration Is 1mg/mL?

50μg at 1mg/mL equals 50μL. Deliverable with a standard 0.5mL insulin syringe marked in 10μL increments. The challenge is measurement precision: a 5μL error (one tick mark) represents a 10% dosing variance. For protocols requiring sub-100μg precision, consider reconstituting to 0.5mg/mL instead, where 50μg equals 100μL and measurement error halves. Low-dose research benefits from lower concentrations; high-dose protocols benefit from higher concentrations. The 1mg/mL standard represents the middle ground.

The Unvarnished Truth About CJC-1295 Concentration

Here's the honest answer: most concentration errors in peptide research aren't accidents. They're the result of researchers trying to 'optimise' a process that's already optimised. The 1mg/mL standard exists because it's been validated across thousands of protocols in academic and commercial settings. Deviating from it doesn't make you more precise. It introduces variability that you can't control or measure without high-performance liquid chromatography (HPLC) equipment. If you're running a multi-subject study and half your reconstituted vials are at 0.8mg/mL and half are at 1.2mg/mL because you eyeballed the diluent volume, your data is compromised before the first injection. Precision matters. Standardisation matters. Use a calibrated syringe, measure twice, and follow the 1mg/mL protocol exactly. Or your results won't replicate, and you won't know why.

Our experience working with research teams shows that the facilities producing the cleanest data are the ones using the most boring, repeatable processes. The team that reconstitutes every vial identically at 1mg/mL using pre-measured bacteriostatic water and logs every batch with timestamps beats the team using 'optimised' concentrations every single time. Research-grade peptides like those available through Real Peptides are manufactured under USP standards. But that precision is meaningless if the reconstitution step introduces 15% variance. The weakest link in peptide research isn't the synthesis. It's the preparation.

Most peptide research isn't constrained by access to high-purity compounds anymore. Suppliers like Real Peptides deliver research-grade CJC-1295 with third-party purity verification. The constraint is protocol discipline. The difference between a study that replicates and one that doesn't often comes down to whether the researcher measured 2.0mL or 'about 2mL' during reconstitution. That's the gap that concentration standardisation closes.

If you're starting a new protocol and you're tempted to reconstitute at 0.75mg/mL because it 'feels easier' for your dosing math, stop. Use 1mg/mL. Match the published standard. Your future self. The one trying to compare results across batches or explain variance to a review board. Will thank you.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The standard research concentration is 1mg/mL, achieved by reconstituting a 2mg lyophilised vial with 2mL bacteriostatic water. This concentration balances peptide stability, injection volume practicality, and dosing precision — it’s the baseline cited in published growth hormone secretagogue studies and allows typical research doses (100–200μg) to be delivered in 100–200μL volumes using standard insulin syringes.

2mg/mL is acceptable for experienced researchers who need lower injection volumes, but concentrations above 2.5mg/mL introduce significant aggregation risk — visible turbidity can appear within 7–10 days even under proper refrigeration. While higher concentrations reduce injection volume (100μL for a 200μg dose at 2mg/mL vs 200μL at 1mg/mL), they also amplify measurement error: a 5μL syringe variance at 2mg/mL delivers 10μg dosing error vs 5μg at 1mg/mL. Unless your protocol specifically requires micro-volume dosing, 1mg/mL remains the safer standard.

When stored at 2–8°C in bacteriostatic water, CJC-1295 at 1mg/mL retains 95–97% potency for 28 days — degradation is approximately 3–5% over that period. Stability degrades sharply if the vial experiences any temperature excursion above 8°C, even briefly. Bacteriostatic water (containing 0.9% benzyl alcohol) is required for this timeline — sterile water lacks antimicrobial preservatives and should be discarded within 24 hours of reconstitution.

If you reconstitute at a lower concentration than intended (e.g., 0.5mg/mL instead of 1mg/mL), the peptide remains usable but every dose requires double the injection volume — a 200μg dose becomes 400μL instead of 200μL, which may exceed practical subcutaneous injection limits. Higher-than-intended concentrations (e.g., 2.5mg/mL) increase aggregation risk and reduce stability. You cannot correct concentration errors by adding or evaporating solvent after reconstitution — discard the batch and start fresh.

Bacteriostatic water is required for any peptide stored longer than 24 hours. It contains 0.9% benzyl alcohol, which prevents bacterial growth during the 28-day refrigerated storage period. Sterile water lacks this preservative and must be discarded within 24 hours — it’s only appropriate for single-use protocols. Never use saline (sodium chloride solution) for peptide reconstitution — the ionic strength destabilises many peptide structures, including CJC-1295.

Divide the total peptide mass (in mg) by the desired concentration (in mg/mL). For 1mg/mL concentration: a 2mg vial requires 2mL, a 5mg vial requires 5mL. For 0.5mg/mL: a 2mg vial requires 4mL. Always use a calibrated syringe or pipette — eyeballing volumes introduces 10–20% error, which compounds across every dose drawn from that vial.

Aggregation appears as visible cloudiness, turbidity, or floating particles in the reconstituted solution — it indicates that individual peptide molecules have clumped together and lost bioactivity. Prevention requires staying below 2mg/mL concentration, maintaining refrigeration at 2–8°C without temperature fluctuations, and injecting bacteriostatic water slowly down the vial wall (never directly onto the powder). If your peptide looks cloudy within 10–14 days at 1mg/mL, check your refrigerator’s actual temperature with a separate thermometer — many household units cycle between 4–10°C, and that upper range accelerates aggregation.

Freezing reconstituted peptides is not recommended. Freeze-thaw cycles cause ice crystal formation, which mechanically shears peptide structures and denatures them. If you must store peptide long-term, keep it lyophilised (unreconstituted powder) at −20°C, where it remains stable for 12–24 months. Only reconstitute the amount you’ll use within 28 days, then refrigerate that portion at 2–8°C.

The 1mg/mL standard refers to concentration (mass per volume), not total vial content. A 2mg vial reconstituted with 2mL yields 1mg/mL concentration — that’s 1 milligram of peptide in every millilitre of solution. This allows precise volumetric dosing: drawing 200μL delivers exactly 200μg. If vials were sold as ‘1mg total’ without specifying reconstitution volume, dosing precision would depend entirely on how much diluent the researcher added, making cross-study comparison impossible.

For doses below 100μg, consider reconstituting to 0.5mg/mL instead of 1mg/mL. A 50μg dose at 1mg/mL requires 50μL injection volume — measurable with a standard insulin syringe, but a 5μL measurement error represents 10% variance. At 0.5mg/mL, that same 50μg dose becomes 100μL, and the same 5μL error drops to 5% variance. Lower concentrations improve dosing precision for low-dose protocols but require larger injection volumes for higher doses.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA